Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GSK)
NYSE:GSK
GSK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$31.72 - $42.63
Previous CloseN/A
Volume981.79K
Average Volume (3M)3.56M
Market Cap
$80.79B
Enterprise Value$97.13B
Total Cash (Recent Filing)$3.62B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)18.4
Beta0.30
Next Earnings
Oct 29, 2025EPS Estimate
1.24Last Dividend Ex-Date
Aug 15, 2025Dividend Yield4.09%
Share Statistics
EPS (TTM)1.24
Shares Outstanding2,034,081,900
10 Day Avg. Volume4,236,355
30 Day Avg. Volume3,564,858
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue3.07
Enterprise Value/Gross Profit4.30
Enterprise Value/Ebitda11.28
Forecast
1Y Price Target
$43.00Price Target Upside6.70% Upside
Rating ConsensusHold
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyThe acquisition of efimosfermin is sound given that it expands GSK's hepatology portfolio, provides optionality to related diseases, and fits within GSK's BD strategy.
Pipeline DevelopmentKey launches and pipeline catalysts over the next 12 months should build confidence in GSK's £40B sales target by 2031, the majority of which is from on-market products.
Product DevelopmentThe launch of depemokimab is another inflection point given the opportunity biologics have to further penetrate the respiratory market.
Product LaunchesBlenrep's U.S. PDUFA and commercial launches will be key factors in achieving GSK's target.
Bears Say
External ChallengesDespite the uncertain external environment, GSK is confident in its ability to navigate challenges.
Sales Target ConcernsGSK noted the majority (50%+) of its 2031 sales target of £40B is from products already on the market.
GlaxoSmithKline News
GSK FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest stock price was $31.71 and its highest was $42.63 in the past 12 months.
What is GlaxoSmithKline’s market cap?
GlaxoSmithKline’s market cap is $80.79B.
When is GlaxoSmithKline’s upcoming earnings report date?
GlaxoSmithKline’s upcoming earnings report date is Oct 29, 2025 which is in 40 days.
How were GlaxoSmithKline’s earnings last quarter?
GlaxoSmithKline released its earnings results on Jul 30, 2025. The company reported $1.236 earnings per share for the quarter, beating the consensus estimate of $1.171 by $0.065.
Is GlaxoSmithKline overvalued?
According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued.
Does GlaxoSmithKline pay dividends?
GlaxoSmithKline pays a Quarterly dividend of $0.428 which represents an annual dividend yield of 4.09%. See more information on GlaxoSmithKline dividends here
What is GlaxoSmithKline’s EPS estimate?
GlaxoSmithKline’s EPS estimate is 1.24.
How many shares outstanding does GlaxoSmithKline have?
GlaxoSmithKline has 2,034,081,900 shares outstanding.
What happened to GlaxoSmithKline’s price movement after its last earnings report?
GlaxoSmithKline reported an EPS of $1.236 in its last earnings report, beating expectations of $1.171. Following the earnings report the stock price went up 3.434%.
Which hedge fund is a major shareholder of GlaxoSmithKline?
Currently, no hedge funds are holding shares in GSK
GlaxoSmithKline Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$43.00 (6.70% Upside)
$43.00 (6.70% Upside)
Blogger Sentiment
Bullish
GSK Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 3.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.75%
12-Months-Change
Fundamentals
Return on Equity
23.04%
Trailing 12-Months
Asset Growth
10.63%
Trailing 12-Months
Company Description
GlaxoSmithKline
GlaxoSmithKline (GSK) is a global healthcare company headquartered in the United Kingdom, dedicated to helping people live healthier lives. The company operates in three main sectors: Pharmaceuticals, Vaccines, and Consumer Healthcare. GSK's pharmaceutical division focuses on innovative medicines across various therapeutic areas, including respiratory, HIV, oncology, and immunology. The vaccines segment is renowned for developing and manufacturing vaccines to protect against infectious diseases, while the consumer healthcare division offers a range of over-the-counter products, including oral health, pain relief, respiratory, and nutritional products.
GSK Company Deck
GSK Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
GSK reported strong financial performance with significant growth in Specialty Medicines and vaccines. However, challenges in supply chain costs, regulatory delays for Blenrep, and difficulties in the Chinese market were notable concerns.View all GSK earnings summariesGSK Stock 12 Month Forecast
Average Price Target
$43.00
▲(6.70% Upside)
Technical Analysis
Ownership Overview
―
Insiders
6.57% Mutual Funds
10.50% Other Institutional Investors
82.70% Public Companies and
Individual Investors